Who Owns Stoke Therapeutics Stock?
NASDAQ: STOKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 117.98%
- Institutions (% of float)
- 122.42%
- Held by insiders
- 3.62%
- Institutional holders
- 260
- Institutions 96.4%
- Insiders 3.6%
- Public and other 0.0%
Who owns Stoke Therapeutics stock?
Institutional investors own about 118.0% of Stoke Therapeutics's shares, spread across 260 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 3.62% of STOK.
The largest institutional holders are Blackrock Inc. (9.71%), RTW Investments LP (8.60%) and FMR, LLC (7.65%). Together, the top 10 institutions control 63.6% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their STOK positions and 5 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of STOK
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Blackrock Inc. | 6.35M | 9.71% | +8.0% |
| RTW Investments LP | 5.62M | 8.60% | 0.0% |
| FMR, LLC | 5.00M | 7.65% | -5.9% |
| Wellington Management Group, LLP | 4.68M | 7.16% | +33.0% |
| Lynx1 Capital Management Lp | 3.90M | 5.96% | -3.5% |
| Redmile Group, LLC | 3.87M | 5.92% | -1.9% |
| BVF Inc. | 3.61M | 5.52% | +41.7% |
| Morgan Stanley | 3.21M | 4.91% | -7.0% |
| Vanguard Capital Management LLC | 2.73M | 4.18% | +5.7% |
| State Street Corporation | 2.62M | 4.00% | -8.2% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of STOK
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.26M | 3.46% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.88M | 2.88% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.49M | 2.28% |
| iShares Trust-iShares Russell 2000 ETF | 1.43M | 2.18% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.31M | 2.01% |
| T. Rowe Price New Horizons Fund, Inc. | 729.20K | 1.11% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 643.54K | 0.98% |
| Fidelity Select Portfolios-Select Health Care Portfolio | 628.00K | 0.96% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 603.19K | 0.92% |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 520.83K | 0.80% |
Frequently asked questions
Who is the largest shareholder of Stoke Therapeutics?
Blackrock Inc. is the largest institutional shareholder of STOK, owning 9.71% of shares outstanding (6.35M shares) as of its latest 13F filing.
What percentage of Stoke Therapeutics is owned by institutions?
Institutions own about 118.0% of STOK shares and 122.4% of the public float.
How much of Stoke Therapeutics do insiders own?
Insiders, such as officers and directors, own about 3.62% of STOK shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.